Low plasma adiponectin levels in obsessive-compulsive disorder

Similarities and differences between eating disorders and obsessive-compulsive disorder in childhood and adolescence: a systematic review

Background

The developmental age, comprising childhood and adolescence, constitutes an extremely important phase of neurodevelopment during which various psychiatric disorders can emerge. Obsessive-Compulsive Disorder (OCD) and Eating Disorders (ED) often manifest during this critical developmental period sharing similarities but also differences in psychopathology, neurobiology, and etiopathogenesis. The aim of this study is to focus on clinical, genetic and neurobiological similarities and differences in OCD and ED.

Methods

This study is based on a PubMed/MEDLINE and Cochrane Central Register for Controlled Trial (CENTRAL). The research adhered to the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

Results

The aforementioned search yielded an initial collection of 335 articles, published from 1968 to September 2023. Through the application of inclusion and exclusion criteria, a total of 324 articles were excluded, culminating in a final selection of 10 articles.

Conclusions

Our findings showed both differences and similarities between OCD and ED. Obsessive-compulsive (OC) symptoms are more prevalent in ED characterized by a binge/purge profile than in those with a restrictive profile during developmental age. OC symptomatology appears to be a common dimension in both OCD and ED. When presents, OC symptomatology, exhibits transversal characteristic alterations in the anterior cingulate cortex and poorer cognitive flexibility. These correlations could be highlighted by genetic overlaps between disorders. A comprehensive definition, integrating psychopathological and neurobiological aspects could significantly aid treatment selection and thereby influence the prognosis of these patients.

Association between Obsessive-Compulsive Symptoms and Long-Term Cardiac Outcomes in Patients with Acute Coronary Syndrome: Effects of Depression Comorbidity and Treatment

OBJECTIVE

The role of obsessive-compulsive symptoms (OCS) in patients with acute coronary syndrome (ACS) is not well elucidated. This study investigated the association between OCS and the long-term prognosis of ACS in tandem with depression comorbidity and treatment.

METHODS

A cross-sectional baseline study and a nested 24-week double-blind escitalopram-placebo controlled trial were carried out between May 2007 and March 2013, and then a 5-12-year follow-up for major adverse cardiac events (MACE) was conducted. A total of 1,152 patients with ACS were stratified by baseline depression comorbidity and treatment allocation into four groups: no depression (706 patients), depression and taking escitalopram (149 patients), depression and taking a placebo (151 patients), and depression and receiving medical care as usual (CAU; 146 patients). OCS were evaluated using the Symptom Checklist-90-Revised Obsessive-Compulsive symptom domain. During the follow-up, Kaplan-Meier event rates for MACE outcomes were calculated, and hazard ratios were estimated using Cox regression models after adjusting for a range of covariates.

RESULTS

A higher OCS score at baseline was associated with a worse ACS prognosis after adjusting for relevant covariates and across MACE outcomes. This association varied according to the depression comorbidity. The association was significant in patients without depression and depressive patients receiving placebos and CAU, but not in depressive patients on escitalopram.

CONCLUSION

Evaluating OCS and depression is recommended during the early phase of ACS. Treatment for OCS may improve the longterm cardiac outcomes of patients with ACS.

Decreased serum levels of adiponectin in adult attention deficit hyperactivity disorder

The main aim of this study was to investigate serum levels of adiponectin in adult patients with attention deficit hyperactivity disorder (ADHD). The second objective was to examine the effects of rare missense mutations in T-cadherin, an adiponectin receptor encoded by the ADHD candidate gene CDH13, on serum adiponectin levels. Total and high molecular weight (HMW) adiponectin levels were measured by an enzyme-linked immunosorbent assay in 44 patients and 29 controls. We found decreased serum adiponectin levels in ADHD patients. In a logistic regression model, adjusting for confounding by age, body mass index, and gender, HMW adiponectin and its ratio to total adiponectin were significantly associated with ADHD. In partial correlations, HMW adiponectin and its ratio to total adiponectin were significantly inversely correlated with self-reported psychiatric symptomatology. A non significant trend for higher levels of total adiponectin was observed in patients carrying CDH13 missense mutations compared to patients with wild type CDH13. The association of CDH13 mutations with adiponectin levels should be investigated in larger studies. This study shows that ADHD patients have decreased serum adiponectin levels, which are inversely correlated to psychiatric symptoms, suggesting a possible involvement of adiponectin, in particular the HMW form, in the pathophysiology of ADHD.

Low plasma adiponectin levels in panic disorder

BACKGROUND

The present study was performed to evaluate plasma adiponectin levels in the patients with PD.

METHOD

The study group included a total of 28 patients (17 females, 11 males) and 23 age- and sex-matched healthy comparison subjects (10 females and 13 males). The plasma fasting glucose, total cholesterol, triglyceride, low density lipoprotein (LDL), high density lipoprotein (HDL), and hemoglobin were measured.

RESULTS

There were no differences in regard to plasma fasting glucose, total cholesterol, triglyceride, LDL, HDL, and hemoglobin levels between groups. However, the mean adiponectin levels were significantly lower in the patient group (26.96 ± 9.92 ng/ml) compared to controls (37.63 ± 23.17 ng/ml) (t=-2.21; p=0.032). As for the ANCOVA analyses, it revealed the main effect of diagnosis on adiponectin levels (F=5.78, p=0.020) after BMI (body mass index) and gender as covariates.

CONCLUSIONS

Consequently, the findings of our study suggest that there may be an interaction between panic disorder and plasma adiponectin. Moreover, they led us to consider that these patients should be also followed as cardiac problems.

Plasma adiponectin elevation in elderly individuals with subsyndromal depression

Adiponectin, one of the adipokines, has believed to play a role in developing of depression, but the relationship between plasma adiponectin and depressive disorder is still unclear. To investigate the association between plasma adiponectin and depressive disorders, we measured plasma adiponectin concentrations in 785 randomly sampled elderly Koreans including 41 patients with major depressive disorder (MDD), 46 with minor depressive disorder (MnDD), and 61 with subsyndromal depression (SSD). Plasma adiponectin levels were different among the diagnostic groups (df=3, F=4.928, P=0.002). The plasma adiponectin level in the SSD patients was higher than in the non-depressed controls (NC) (12.48 ± 8.38 μg/ml versus 9.27 ± 6.21 μg/ml, P=0.001, Tukey's post hoc comparison). However, plasma adiponectin levels in the MnDD and MDD patients were comparable with those found in the NC (P>0.1, Tukey's post hoc comparison). The elevation of plasma adiponectin in the SSD patients remained significant in men (P=0.002, Tukey's post hoc comparison) but not in women. In the subjects without MDD and MnDD, plasma adiponectin level was positively correlated with the Hamilton Depression Rating Scale score (r=0.156, P<0.001) and the Geriatric Depression Scale (r=0.117, P=0.002). When men and women were analyzed separately, these significant correlations were confined to men. Circulating adiponectin concentration may play a role in compensation on process for depressive mood.

Serum adiponectin and resistin levels in patients with obsessive compulsive disorder

We aimed to investigate the changes in serum adiponectin and resistin levels in patients with obsessive compulsive disorder and control groups. The serum adiponectin and resistin levels of 29 patients (16 females, 13 males) with obsessive compulsive disorder and weight, age and sex-matched 31 healthy controls (17 females, 14 males) were determined. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) was applied to all groups. ELISA method was used to measure adiponectin and resistin levels. The mean adiponectin level was 11.92±2.04 ng/ml and resistin level was 13.23±2.78 ng/ml in obsessive compulsive disorder group, while it was 18.81±5.24 ng/ml and 8.17±2.53 ng/ml in control group. Changes in plasma adiponectin and resistin levels in obsessive compulsive disorder may have implications about possible cardiovascular and metabolic abnormalities seen in obsessive compulsive patients.